NYSE:CORHealthcare
Is Cencora’s Rare-Disease Commercialization Push With Curant Reshaping Its Investment Narrative (COR)?
In January 2026, Curant Health's Curant Rare announced a collaboration with Cencora to offer an integrated commercialization solution for rare disease therapies, combining Cencora’s logistics, pharmacovigilance and market access support with Curant Rare’s specialty pharmacy and patient engagement services.
A distinctive aspect of this partnership is its focus on real-world evidence and patient-reported outcomes, aiming to improve both market access and the overall patient experience in rare...